Chugai Starts RenaGel Trials

9 December 1996

- Chugai Pharmaceuticals has initiated Phase I trials in Japan with RenaGel (licensed from GelTex), for the management of elevated phosphate levels in chronic kidney failure patients. Patients will start receiving RenaGel in early 1997. GelTex is conducting Phase III trials with the product in the USA; one is a dose-titration study, and the second will determine its safety compared to calcium-based phosphate binders. These are expected to be completed in first-quarter 1997.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight